Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome

描述（由申请人提供）：一种体外装置，称为选择性细胞增生装置（SCD），已被制造出来，可隔离活化的白细胞并抑制其释放炎症蛋白和细胞因子。白细胞是许多临床炎症性疾病的发病和进展的主要贡献者，包括全身性炎症反应综合征（SIRS）、败血症和急性呼吸窘迫综合征（ARDS）。目前正在研究大量的治疗方法，以限制炎症部位白细胞的激活和组织积聚，以尽量减少组织破坏和疾病进展。本研究计划将在成熟的猪感染性休克、SIRS和早期ARDS模型上对SCD进行评估。将治疗组和假治疗组的各种心血管参数、全身细胞因子水平、肺部炎症伴支气管肺泡灌洗（BAL）参数和死亡时间进行比较。膜表面积和简化电路系统对正在进行的多器官功能障碍和炎症过程的影响也将被评估。这一建议可能提示一种改变全身炎症反应的方式，并可能导致败血症，SIRS和ARDS的新治疗方法。

DESCRIPTION (provided by applicant): An extracorporeal device, named selective cytopheretic device (SCD), has been fabricated that sequesters activated leukocytes and inhibits their release of inflammatory proteins and cytokines. Leukocytes are major contributors to the pathogenesis and progression of many clinical inflammatory disorders, including the systemic inflammatory response syndrome (SIRS), sepsis and acute respiratory distress syndrome (ARDS). A large number of therapeutic approaches are under investigation to limit the activation and tissue accumulation of leukocytes at sites of inflammation in order to minimize tissue destruction and disease progression. This research proposal will evaluate this SCD on a well-developed porcine model of septic shock, SIRS and early ARDS. Various cardiovascular parameters, systemic cytokine levels, and pulmonary inflammation with bronchoalveolar lavage (BAL) parameters and time to death will be compared between treatment and sham treatment groups. The effects of membrane surface area and efficacy of a simplified circuit system on the ongoing multiorgan dysfunction and inflammatory processes will also be assessed. This proposal may suggest a manner of altering the systemic inflammatory response and may lead to a new therapeutic approach to sepsis, SIRS and ARDS.